01 Expansion of Vaccines for Emerging and Transboundary Animal Diseases Veterinary vaccine development is increasingly responding to diseases that can cause major livestock losses and disrupt animal movement and trade. Research organizations and manufacturers are working on vaccines for diseases where existing control measures remain limited, creating new product opportunities for livestock health and disease preparedness. This is broadening the veterinary vaccine pipeline beyond established vaccination programs.In April 2026, ICAR transferred technology for an indigenous live-attenuated lumpy skin disease vaccine to Brilliant Bio Pharma in India. The technology was developed for cattle and was intended to support large-scale production and wider distribution of the vaccine across the livestock sector.
02 Development of New Generation Veterinary Vaccines The veterinary vaccine industry is expanding beyond conventional vaccine technologies as manufacturers introduce products using recombinant, subunit, and other advanced approaches. These technologies can be designed for specific pathogens and may offer advantages in safety, targeting, or disease-control strategies. The emergence of new vaccine platforms is creating greater technological diversity within the veterinary vaccines market.In 2025, the European Medicines Agency listed several new veterinary vaccines, including a vaccine against Brachyspira hyodysenteriae infections in pigs and a recombinant-protein vaccine against bluetongue virus serotype 3. The approvals demonstrate continued development of vaccines for different livestock species and disease targets.
01 Expansion of Livestock Disease-Control Programs Supports Vaccine Consumption Government disease-control programs create direct demand for veterinary vaccines because vaccination is used to reduce disease prevalence, protect livestock populations, and limit economic losses from outbreaks. Organized vaccination campaigns can generate substantial requirements for vaccines when authorities target specific high-risk animal populations or geographic regions. This supports veterinary vaccines market demand beyond routine private-sector veterinary use.In 2026, WOAH's Vaccine Bank mechanism supported the delivery of 1.15 million doses of peste des petits ruminants vaccine to Kenya under the PC-TAD project. The program also supplied cold-chain and vaccination equipment to support implementation in targeted high-risk counties.
01 Temperature-Sensitive Products Increase Distribution Requirements Many veterinary vaccines require controlled storage and transportation conditions to maintain their effectiveness. Maintaining appropriate temperatures throughout transportation, storage, and administration requires specialized equipment, monitoring, trained personnel, and reliable logistics. These requirements can increase distribution costs and make vaccine delivery more difficult in areas where cold-chain infrastructure is limited.In July 2025, the World Health Organization issued its seventh edition of international vaccine packaging and shipping guidelines, highlighting temperature control, quality checks, packaging requirements, and transportation conditions as important considerations in international vaccine shipments. Although the guidelines cover vaccines broadly, the logistics requirements are directly relevant to temperature-sensitive veterinary vaccine supply chains.
01 Commercialization of Locally Developed Veterinary Vaccine Technologies Technology transfer from research institutions to private manufacturers is creating opportunities to expand domestic veterinary vaccine production. Local manufacturing can provide additional production capacity for diseases that have major regional livestock impacts and can reduce dependence on imported products. Partnerships between research institutions and pharmaceutical manufacturers can therefore accelerate commercialization and broaden vaccine availability.In April 2026, ICAR commercialized its lumpy skin disease vaccine technology through a licensing agreement with Brilliant Bio Pharma. The agreement included a ₹75 lakh technology licensing fee plus a 5% royalty on sales and represented the sixth company to receive the technology.
01 Maintaining Vaccine Quality Through Procurement and Field Administration Veterinary vaccine effectiveness depends not only on product development but also on appropriate procurement, quality assessment, storage, handling, and administration. Differences in veterinary infrastructure and implementation capacity can make it difficult to maintain consistent vaccination quality after products leave manufacturing facilities. This creates challenges for governments and veterinary services implementing large-scale disease-control programs.In May 2025, WOAH's veterinary vaccine technical forum emphasized the need to strengthen vaccination systems through science-based policies, improved implementation, and better coordination between stakeholders. The organization linked effective vaccination with animal health, zoonotic-disease prevention, antimicrobial-use reduction, and broader One Health objectives.
June 2026 Merck Animal Health announced the acquisition of TARGAN, expanding its poultry vaccine technology portfolio with advanced in-ovo vaccination and precision animal health solutions.
June 2026 Zoetis reported receiving regulatory approvals for innovative vaccines, including new vaccine solutions targeting avian influenza in poultry and dairy cattle, strengthening its livestock vaccine portfolio.
February 2026 Elanco Animal Health received USDA approval for TruCan™ Ultra Lyme-L4, the first and only 0.5 mL combination vaccine protecting dogs against Lyme disease and leptospirosis, expanding its companion animal vaccine portfolio.
July 2025 Ceva Santé Animale and Touchlight expanded their strategic collaboration to accelerate the development and manufacturing of DNA-based veterinary vaccines, strengthening innovation in next-generation animal vaccine technologies.